Terms: = Ovarian cancer AND NTRK1, ENSG00000198400, 4914, P04629, TRK1, MTC, DKFZp781I14186, p140-TrkA, TRKA, TRK
48 results:
1.
Mulkidjan RS; Saitova ES; Preobrazhenskaya EV; Asadulaeva KA; Bubnov MG; Otradnova EA; Terina DM; Shulga SS; Martynenko DE; Semina MV; Belogubova EV; Tiurin VI; Amankwah PS; Martianov AS; Imyanitov EN
Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686416
[TBL] [Abstract] [Full Text] [Related]
2. Hydrazide-hydrazones as Small Molecule Tropomyosin Receptor Kina se A (trka) Inhibitors: Synthesis, Anticancer Activities,
Alam MS; Lee DU
Med Chem; 2022; 19(1):47-63. PubMed ID: 35490310
[TBL] [Abstract] [Full Text] [Related]
3. NGF/trka Promotes ADAM17-Dependent Cleavage of P75 in ovarian Cells: Elucidating a Pro-Tumoral Mechanism.
Garrido MP; Vallejos C; Girardi S; Gabler F; Selman A; López F; Vega M; Romero C
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216240
[TBL] [Abstract] [Full Text] [Related]
4. Cystic ovarian teratoma as a novel tumor and growth hormone deficiency as a new condition presenting in Multiple Endocrine Neoplasia type 2B: Case reports and review of the literature.
Pomahacova R; Paterova P; Nykodymova E; Vaclavikova E; Sykorova P; Personova K; Katra R; Subrt I; Sykora J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Mar; 166(1):105-111. PubMed ID: 34446941
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic and Theranostic Biomarkers in ovarian Clear Cell Carcinoma.
Wiedemeyer K; Wang L; Kang EY; Liu S; Ou Y; Kelemen LE; Feil L; Anglesio MS; Glaze S; Ghatage P; Nelson GS; Köbel M
Int J Gynecol Pathol; 2022 Mar; 41(2):168-179. PubMed ID: 33770057
[TBL] [Abstract] [Full Text] [Related]
6. NGF/trka Decrease miR-145-5p Levels in Epithelial ovarian cancer Cells.
Garrido MP; Torres I; Avila A; Chnaiderman J; Valenzuela-Valderrama M; Aramburo J; Oróstica L; Durán-Jara E; Lobos-Gonzalez L; Romero C
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081171
[TBL] [Abstract] [Full Text] [Related]
7. Follicle-stimulating hormone promotes nerve growth factor and vascular endothelial growth factor expression in epithelial ovarian cells.
Garrido MP; Bruneau N; Vega M; Selman A; Tapia JC; Romero C
Histol Histopathol; 2020 Sep; 35(9):961-971. PubMed ID: 32369181
[TBL] [Abstract] [Full Text] [Related]
8. Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing.
Kim SI; Lee JW; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS; Seo JS
Gynecol Oncol; 2018 Feb; 148(2):375-382. PubMed ID: 29233531
[TBL] [Abstract] [Full Text] [Related]
9. Role of Nerve Growth Factor (NGF) and miRNAs in Epithelial ovarian cancer.
Retamales-Ortega R; Oróstica L; Vera C; Cuevas P; Hernández A; Hurtado I; Vega M; Romero C
Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28245631
[TBL] [Abstract] [Full Text] [Related]
10. Clinical and genetic determinants of ovarian metastases from colorectal cancer.
Ganesh K; Shah RH; Vakiani E; Nash GM; Skottowe HP; Yaeger R; Cercek A; Lincoln A; Tran C; Segal NH; Reidy DL; Varghese A; Epstein AS; Sonoda Y; Chi D; Guillem J; Temple L; Paty P; Hechtman J; Shia J; Weiser M; Aguilar JG; Kemeny N; Berger MF; Saltz L; Stadler ZK
Cancer; 2017 Apr; 123(7):1134-1143. PubMed ID: 27875625
[TBL] [Abstract] [Full Text] [Related]
11. Synthesis, anticancer, and docking studies of salicyl-hydrazone analogues: A novel series of small potent tropomyosin receptor kinase A inhibitors.
Alam MS; Choi SU; Lee DU
Bioorg Med Chem; 2017 Jan; 25(1):389-396. PubMed ID: 27856237
[TBL] [Abstract] [Full Text] [Related]
12. Role of nerve growth factor and its trka receptor in normal ovarian and epithelial ovarian cancer angiogenesis.
Vera C; Tapia V; Vega M; Romero C
J Ovarian Res; 2014 Aug; 7():82. PubMed ID: 25296882
[TBL] [Abstract] [Full Text] [Related]
13. A novel multiple tyrosine-kinase targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of multiple solid tumors: cabozantinib.
Roy S; Narang BK; Rastogi SK; Rawal RK
Anticancer Agents Med Chem; 2015; 15(1):37-47. PubMed ID: 25181996
[TBL] [Abstract] [Full Text] [Related]
14. Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor.
Grüllich C
Recent Results Cancer Res; 2014; 201():207-14. PubMed ID: 24756794
[TBL] [Abstract] [Full Text] [Related]
15. Hydrophobic modification of low molecular weight polyethylenimine for improved gene transfection.
Teo PY; Yang C; Hedrick JL; Engler AC; Coady DJ; Ghaem-Maghami S; George AJ; Yang YY
Biomaterials; 2013 Oct; 34(32):7971-9. PubMed ID: 23880339
[TBL] [Abstract] [Full Text] [Related]
16. Promoter methylation of GATA4, WIF1, ntrk1 and other selected tumour suppressor genes in ovarian cancer.
Chmelařová M; Dvořáková E; Špaček J; Laco J; Mžik M; Palička V
Folia Biol (Praha); 2013; 59(2):87-92. PubMed ID: 23746174
[TBL] [Abstract] [Full Text] [Related]
17. Functional proteomics, human genetics and cancer biology of GIPC family members.
Katoh M
Exp Mol Med; 2013 Jun; 45(6):e26. PubMed ID: 23743496
[TBL] [Abstract] [Full Text] [Related]
18. Nerve growth factor induces the expression of chaperone protein calreticulin in human epithelial ovarian cells.
Vera C; Tapia V; Kohan K; Gabler F; Ferreira A; Selman A; Vega M; Romero C
Horm Metab Res; 2012 Jul; 44(8):639-43. PubMed ID: 22773372
[TBL] [Abstract] [Full Text] [Related]
19. Trabectedin for the treatment of relapsed ovarian cancer.
Papaioannou D; Rafia R; Stevenson MD; Stevens JW; Evans P
Health Technol Assess; 2011 May; 15 Suppl 1():69-75. PubMed ID: 21609655
[TBL] [Abstract] [Full Text] [Related]
20. Metastatic medullary thyroid cancer presenting with elevated levels of CA 19-9 and CA 125.
Milman S; Whitney KD; Fleischer N
Thyroid; 2011 Aug; 21(8):913-6. PubMed ID: 21751886
[TBL] [Abstract] [Full Text] [Related]
[Next]
